DDInter1770 DDInter1658
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Terfenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lasmiditan
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Terfenadine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Terfenadine {u} may lead to a major life threatening interaction when taken with {v} Citalopram
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Terfenadine may lead to a major life threatening interaction when taken with Crizotinib
Terfenadine may lead to a major life threatening interaction when taken with Citalopram